These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35312724)

  • 1. Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma.
    Sangsuwannukul T; Supimon K; Chieochansin T; Choomee K; Sujjitjoon J; Junking M; Yenchitsomanus PT
    PLoS One; 2022; 17(3):e0265773. PubMed ID: 35312724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.
    Suwanchiwasiri K; Phanthaphol N; Somboonpatarakun C; Yuti P; Sujjitjoon J; Luangwattananun P; Maher J; Yenchitsomanus PT; Junking M
    Biomed Pharmacother; 2024 Jun; 175():116718. PubMed ID: 38744221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.
    Luangwattananun P; Sangsuwannukul T; Supimon K; Thuwajit C; Chieochansin T; Sa-Nguanraksa D; Samarnthai N; O-Charoenrat P; Junking M; Yenchitsomanus PT
    Int Immunopharmacol; 2023 Nov; 124(Pt B):111012. PubMed ID: 37804657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.
    Supimon K; Sangsuwannukul T; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
    Sci Rep; 2021 Mar; 11(1):6276. PubMed ID: 33737613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells.
    Sangsuwannukul T; Supimon K; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107069. PubMed ID: 33242709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.
    Wathikthinnakon M; Luangwattananun P; Sawasdee N; Chiawpanit C; Lee VS; Nimmanpipug P; Tragoolpua Y; Rotarayanont S; Sangsuwannukul T; Phanthaphol N; Wutti-In Y; Somboonpatarakun C; Chieochansin T; Junking M; Sujjitjoon J; Yenchitsomanus PT; Panya A
    Sci Rep; 2022 Apr; 12(1):6154. PubMed ID: 35418130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings.
    Petersburg J; Vallera DA; Wagner CR
    Mol Cancer Ther; 2023 Mar; 22(3):371-380. PubMed ID: 36548194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
    Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
    Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.
    Liu R; Zhao R; Zhou X; Liang X; Campbell DJ; Zhang X; Zhang L; Shi R; Wang G; Pandak WM; Sirica AE; Hylemon PB; Zhou H
    Hepatology; 2014 Sep; 60(3):908-18. PubMed ID: 24700501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines.
    Samatiwat P; Tabtimmai L; Suphakun P; Jiwacharoenchai N; Toviwek B; Kukongviriyapan V; Gleeson MP; Choowongkomon K
    Asian Pac J Cancer Prev; 2021 Feb; 22(2):381-390. PubMed ID: 33639651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells.
    Thepmalee C; Panya A; Sujjitjoon J; Sawasdee N; Poungvarin N; Junking M; Yenchitsomanus PT
    Hum Vaccin Immunother; 2020 Oct; 16(10):2318-2327. PubMed ID: 31976810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers.
    van Diest E; Nicolasen MJT; Kramer L; Zheng J; Hernández-López P; Beringer DX; Kuball J
    Front Immunol; 2022; 13():1052090. PubMed ID: 36685546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
    Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
    J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptor protein XB130 regulates the aggressiveness of cholangiocarcinoma.
    Poosekeaw P; Pairojkul C; Sripa B; Sa Ngiamwibool P; Iamsaard S; Sakonsinsiri C; Thanan R; Ungarreevittaya P
    PLoS One; 2021; 16(11):e0259075. PubMed ID: 34780466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of CXCR4 inhibits tumor cell proliferation and neural invasion in human hilar cholangiocarcinoma.
    Tan XY; Chang S; Liu W; Tang HH
    Gut Liver; 2014 Mar; 8(2):196-204. PubMed ID: 24672662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.
    Cadamuro M; Nardo G; Indraccolo S; Dall'olmo L; Sambado L; Moserle L; Franceschet I; Colledan M; Massani M; Stecca T; Bassi N; Morton S; Spirli C; Fiorotto R; Fabris L; Strazzabosco M
    Hepatology; 2013 Sep; 58(3):1042-53. PubMed ID: 23505219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and characterization of a novel human cholangiocarcinoma cell line with high metastatic activity.
    Uthaisar K; Vaeteewoottacharn K; Seubwai W; Talabnin C; Sawanyawisuth K; Obchoei S; Kraiklang R; Okada S; Wongkham S
    Oncol Rep; 2016 Sep; 36(3):1435-46. PubMed ID: 27461717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.